Impact Biomedical (IBO) Free Cash Flow Growth (3y) (2025 - 2026)

Impact Biomedical (IBO) Free Cash Flow Growth (3y) (2025 - 2026) Analysis & Trends

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Growth (3y) (Qtr)
1	Oculis Holding AG	67,042.03 Bn	67,041.74 Bn	-	-5.05%
2	Nanobiotix	1,908.00 Bn	1,907.94 Bn	-	-
3	Akari Therapeutics	959.56 Bn	959.56 Bn	-	-
4	BeOne Medicines	471.84 Bn	467.05 Bn	1.35 Bn	31.07%
5	Vertex Pharmaceuticals	122.13 Bn	114.88 Bn	2.59 Bn	14.71%
6	Regeneron Pharmaceuticals	70.01 Bn	61.26 Bn	3.31 Bn	-10.65%
7	Belite Bio	62.34 Bn	62.34 Bn	-	-
8	Argenx Se	55.93 Bn	50.74 Bn	1.41 Bn	-
9	Alnylam Pharmaceuticals	37.49 Bn	34.48 Bn	959.66 Mn	31.42%
10	Impact Biomedical	46.36 Mn	46.34 Mn	-	23.07%

Download Data